‹ Today's picks

FTRE (Fortrea Holdings Inc.) — AI Stock Research

Research of October 30, 2026 · Healthcare / Services-Medical Laboratories

TradeFlare's AI research teams rate FTRE a HOLD. The latest price is $21.29.

The research plan

  • Entry: $21.29
  • Time horizon: days

The current market and stock-specific factors do not support a new entry.

Why

FTRE presents a high-risk profile with significant fundamental headwinds, including negative growth, losses, and high leverage. Despite a neutral market regime, the combination of a bearish fundamental outlook, neutral technicals with bearish momentum signals, and a high risk score (9/10) triggers the "HOLD" recommendation based on Rule 1. Specifically, the risk score is ≥ 9 and fewer than 3/3 directional teams are BULLISH, which is a deal-breaker for a BUY. The conviction is set low to reflect

What could push FTRE higher

  • No immediate catalysts are apparent that would override the current bearish fundamental and neutral technical outlook.
  • Any positive news would need to be substantial to overcome the high risk and negative fundamental indicators.
  • The market regime is neutral, offering no strong tailwinds for new speculative positions.

Key risks for FTRE

  • The company exhibits significant financial distress with negative revenue growth, consistent net losses, high leverage, and critically low interest coverage.
  • Technical indicators are showing bearish momentum, and the price is approaching a significant resistance level with subdued volume.
  • High realized volatility and a severe drawdown history indicate a propensity for sharp price movements.

What each AI research team found

Fundamental team: Bearish · valuation: overvalued

Fortrea's current financial performance is concerning, marked by negative revenue growth and persistent net losses, coupled with high leverage and low interest coverage. While the backlog offers some future visibility, the current valuation appears stretched given the lack of profitability and deteriorating competitive position. The BEARISH verdict reflects the significant risks outweighing the potential upside...

  • Fortrea (FTRE) is experiencing negative revenue growth (-1.4% YoY) and consistent net losses, despite a substantial backlog.
  • The company exhibits high leverage with a Debt-to-Equity ratio of 2.10 and critically low interest coverage (0.31x).
  • Valuation metrics like P/S ratio are above historical median, and EV/EBITDA is higher than industry average, while profitability remains negative.

Technical team: Neutral

The stock is in a short-term uptrend but is facing significant resistance at $23.53. Bearish momentum signals and subdued volume suggest a potential pullback. Therefore, a neutral stance is warranted, with a potential short entry if resistance holds, targeting the $20.55 support level.

  • The price is in an uptrend and above the MA20/MA50, but is approaching a significant resistance level.
  • Trading activity is subdued with volume below the 20-day MA, and a recent volume spike on a down day suggests potential distribution.
  • MACD and Stochastic indicators are showing bearish momentum, with RSI neutral, indicating a potential pullback.

Sentiment team: Neutral

Overall sentiment for FTRE is neutral, reflecting a balance between positive Q3 earnings surprises and revenue guidance raises, and concerns over insider selling, backlog reduction, and a cautious near-term outlook. Sentiment momentum is stable, with no clear directional bias emerging from the aggregated analyses. The current neutral stance suggests investors are awaiting further clarity on future growth drivers...

  • Fortrea Holdings (FTRE) news coverage is predominantly neutral, with a slight bullish leaning due to recent earnings beats and positive analyst outlooks, but concerns remain regarding overall profitability and stock rating. (Score: 0.05)
  • Fortrea Holdings (FTRE) exhibits a neutral sentiment driven by mixed Q3 results, with revenue beats and guidance raises offset by earnings misses and a cautious outlook, though bullish options data and analyst ratings provide some support. (Score: 0.05)
  • Fortrea Holdings (FTRE) shows a neutral sentiment driven by mixed analyst ratings and price targets, positive earnings surprises, and forward-looking growth expectations, but tempered by significant insider selling and concerns over backlog reduction....

Risk team: High

FTRE presents an extremely high-risk profile characterized by severe volatility, a deep historical drawdown, and critical financial distress indicated by negative interest coverage and high leverage. The company's high beta further exacerbates market-related risks. Given these factors, a very small position size with aggressive risk management is warranted.

  • High Volatility and Drawdown: FTRE exhibits extremely high realized volatility (67.27% annualized) and a severe 1-year maximum drawdown (-89.92%), indicating substantial price instability and historical downside.
  • Insolvency Risk due to Negative Interest Coverage: The company's operating income is insufficient to cover its interest expenses (interest coverage proxy of 0.31), posing a significant risk of default or financial distress.
  • High Financial Leverage: A high debt-to-equity ratio (2.10) and proxy (4.14) amplify financial risk, especially in a rising interest rate environment or during economic downturns.

FTRE at a glance

Market value$2.3B
Revenue growth (year over year)-2.1%
Profit margin-3.2%
Debt / equity1.98

Every AI call on FTRE since May 11, 2026, and what happened next (14 calls) →

Frequently asked questions

Is FTRE a buy? In its research of October 30, 2026, TradeFlare's AI rated FTRE a HOLD. This is AI-generated research, not financial advice.

When was this analysis last updated? October 30, 2026. Stocks on TradeFlare's lists are re-researched every market night. How the research works.

Research of October 30, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.

Related stocks

UNH UnitedHealth Group IncorporaSGRY Surgery Partners, Inc.OMCL Omnicell, Inc.NTRA Natera, Inc.KNSA Kiniksa Pharmaceuticals InteGILD Gilead Sciences, Inc.
AI research, not financial advice. All of it is generated by software and can be wrong. Terms